Analysis shows benefits of NeuroStar TMS for Depression-Neuronetics

Neuronetics has announced a new analysis that shows Transcranial Magnetic Stimulation (TMS) administered with the NeuroStar TMS Therapy System resulted in greater symptom improvement than next-choice conventional antidepressant medication among patients with Major Depressive Disorder (MDD) who failed to benefit from prior antidepressant medication. In a propensity-score matched analysis of data from two independent studies, patient-reported symptom outcomes measured by the Quick Inventory of Depressive Symptomatology-Self Report (QIDS-SR), showed that after 6 weeks of acute phase treatment, 53 percent of patients treated with NeuroStar TMS Therapy reported no or mild depression.

In contrast, the propensity-score matched population of patients treated with next-choice antidepressant medication showed improvement among 38 percent of patients (P<0.0001 for the contrast between the two groups favoring neurostar tms therapy. a companion study also presented found that neurostar tms therapy is cost-effective for patients who fail to benefit from prior antidepressant medication with mean annual costs of 11886 and 10888 for tms and stard patients respectively. data were presented at the annual meeting of the american psychiatric association.>